Scholarlink

<p>A&#xa0;deeper understanding of tumor cell biology and the mechanisms of resistance development forms the foundation for the development of new therapeutic options for patients with advanced prostate cancer. Promising approaches to specifically targeting the androgen receptor (AR) signaling pathway include early inhibition of steroid hormone synthesis as well as targeted degradation of the AR through the cell’s own proteolytic machinery. Additionally, the inhibition of alternative signaling pathways, such as the PI3K/AKT pathway, may counteract AR-independent tumor progression. Another innovative approach is the use of newly identified surface proteins through radioligand therapy, cytotoxic antibody conjugates, and T‑cell engagers. These various strategies allow for better addressing the heterogeneity of tumor behavior, particularly during disease progression. The successful implementation of these new therapeutic options requires repeated and precise tumor characterization, for example, through liquid biopsy or molecular imaging. In the future, close interdisciplinary collaboration will play an even more central role in optimal patient care. Only through collaboration of various disciplines can the latest scientific findings be rapidly translated into clinical practice and personalized treatment strategies further optimized.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neue Therapiestrategien für das Prostatakarzinom

  • 期刊论文

  • 发表日期：

    2025年7月30日

查看全文
  • Gunhild von Amsberg,
  • Winfried Alsdorf,
  • Anja Coym,
  • Sergey Dyshlovoy,
  • Carsten Bokemeyer,
  • Aurelius Omlin

摘要

A deeper understanding of tumor cell biology and the mechanisms of resistance development forms the foundation for the development of new therapeutic options for patients with advanced prostate cancer. Promising approaches to specifically targeting the androgen receptor (AR) signaling pathway include early inhibition of steroid hormone synthesis as well as targeted degradation of the AR through the cell’s own proteolytic machinery. Additionally, the inhibition of alternative signaling pathways, such as the PI3K/AKT pathway, may counteract AR-independent tumor progression. Another innovative approach is the use of newly identified surface proteins through radioligand therapy, cytotoxic antibody conjugates, and T‑cell engagers. These various strategies allow for better addressing the heterogeneity of tumor behavior, particularly during disease progression. The successful implementation of these new therapeutic options requires repeated and precise tumor characterization, for example, through liquid biopsy or molecular imaging. In the future, close interdisciplinary collaboration will play an even more central role in optimal patient care. Only through collaboration of various disciplines can the latest scientific findings be rapidly translated into clinical practice and personalized treatment strategies further optimized.